Oncolytic Virotherapy of Canine and Feline Cancer

被引：28
作者：
Gentschev, Ivaylo [1 ,2 ]
Patil, Sandeep S. [1 ]
Petrov, Ivan [1 ]
Cappello, Joseph [2 ]
Adelfinger, Marion [1 ]
Szalay, Aladar A. [1 ,2 ,3 ]
机构：
[1] Univ Wurzburg, Dept Biochem, D-97074 Wurzburg, Germany
[2] Genelux Corp, San Diego Sci Ctr, San Diego, CA 92109 USA
[3] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA
来源：
VIRUSES-BASEL | 2014年 / 6卷 / 05期
关键词：
cancer; canine and feline cancer therapy; oncolytic virus; oncolysis; HERPES-SIMPLEX-VIRUS; CELL-BASED DELIVERY; VACCINIA VIRUS; THYMIDINE KINASE; GENE-THERAPY; TUMOR-CELLS; NUDE-MICE; IN-VITRO; PET DOGS; ADENOVIRUS;
D O I：
10.3390/v6052122
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Cancer is the leading cause of disease-related death in companion animals such as dogs and cats. Despite recent progress in the diagnosis and treatment of advanced canine and feline cancer, overall patient treatment outcome has not been substantially improved. Virotherapy using oncolytic viruses is one promising new strategy for cancer therapy. Oncolytic viruses (OVs) preferentially infect and lyse cancer cells, without causing excessive damage to surrounding healthy tissue, and initiate tumor-specific immunity. The current review describes the use of different oncolytic viruses for cancer therapy and their application to canine and feline cancer.
引用
收藏
页码：2122 / 2137
页数：16
相关论文
共 50 条
  • [41] Cytokines in oncolytic virotherapy
    Pol, Jonathan G.
    Workenhe, Samuel T.
    Konda, Prathyusha
    Gujar, Shashi
    Kroemer, Guido
    CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 56 : 4 - 27
  • [42] Oncolytic Virotherapy by HSV
    Watanabe, Daisuke
    Goshima, Fumi
    HUMAN HERPESVIRUSES, 2018, 1045 : 63 - 84
  • [43] Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
    Nakashima, Hiroshi
    Nguyen, Tran
    Chiocca, Ennio Antonio
    ONCOLYTIC VIROTHERAPY, 2015, 4 : 183 - 191
  • [44] Oncolytic virotherapy in cancer treatment: challenges and optimization prospects
    Chen, Lingjuan
    Zuo, Mengsi
    Zhou, Qin
    Wang, Yang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [45] Vaccinia virus and oncolytic virotherapy of cancer
    Thorne, SH
    Hwang, TH
    Kirn, DH
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (04) : 359 - 365
  • [46] Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
    Sadri, Maryam
    Najafi, Alireza
    Rahimi, Ali
    Behranvand, Nafiseh
    Kazemi, Mohammad Hossein
    Khorramdelazad, Hossein
    Falak, Reza
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [47] Oncolytic Virotherapy for Breast Cancer Treatment
    O'Bryan, Samia M.
    Mathis, J. Michael
    CURRENT GENE THERAPY, 2018, 18 (04) : 192 - 205
  • [48] Oncolytic virotherapy as a personalized cancer vaccine
    Li, Qi-Xiang
    Liu, Guohong
    Wong-Staal, Flossie
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (03) : 493 - 499
  • [49] A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model
    Hemminki, A
    Kanerva, A
    Kremer, EJ
    Bauerschmitz, GJ
    Smith, BF
    Liu, B
    Wang, MH
    Desmond, RA
    Keriel, A
    Barnett, B
    Baker, HJ
    Siegal, GP
    Curiel, DT
    MOLECULAR THERAPY, 2003, 7 (02) : 163 - 173
  • [50] Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
    Zou, Hai
    Mou, Xiao-Zhou
    Zhu, Biao
    GLOBAL CHALLENGES, 2023, 7 (01)
12345